- Home
- BWIN vs CPRX Comparison
BWIN vs CPRX Comparison
Compare BWIN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- CPRX
- Stock Information
- Founded
- BWIN 2011
- CPRX 2002
- Country
- BWIN United States
- CPRX United States
- Employees
- BWIN N/A
- CPRX N/A
- Industry
- BWIN Specialty Insurers
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- BWIN Finance
- CPRX Health Care
- Exchange
- BWIN Nasdaq
- CPRX Nasdaq
- Market Cap
- BWIN 3.1B
- CPRX 2.8B
- IPO Year
- BWIN 2019
- CPRX 2006
- Fundamental
- Price
- BWIN $43.93
- CPRX $20.60
- Analyst Decision
- BWIN Buy
- CPRX Strong Buy
- Analyst Count
- BWIN 6
- CPRX 6
- Target Price
- BWIN $46.80
- CPRX $30.50
- AVG Volume (30 Days)
- BWIN 994.7K
- CPRX 1.0M
- Earning Date
- BWIN 11-04-2024
- CPRX 11-06-2024
- Dividend Yield
- BWIN N/A
- CPRX N/A
- EPS Growth
- BWIN N/A
- CPRX 114.68
- EPS
- BWIN N/A
- CPRX 1.18
- Revenue
- BWIN $1,343,793,000.00
- CPRX $460,482,000.00
- Revenue This Year
- BWIN $16.29
- CPRX $21.99
- Revenue Next Year
- BWIN $13.27
- CPRX $17.95
- P/E Ratio
- BWIN N/A
- CPRX $17.48
- Revenue Growth
- BWIN 13.89
- CPRX 32.17
- 52 Week Low
- BWIN $17.33
- CPRX $13.00
- 52 Week High
- BWIN $55.82
- CPRX $24.27
- Technical
- Relative Strength Index (RSI)
- BWIN 40.28
- CPRX 39.71
- Support Level
- BWIN $34.22
- CPRX $21.30
- Resistance Level
- BWIN $49.96
- CPRX $24.27
- Average True Range (ATR)
- BWIN 2.63
- CPRX 0.79
- MACD
- BWIN -0.30
- CPRX -0.18
- Stochastic Oscillator
- BWIN 56.03
- CPRX 4.18
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.